Unbroken supersymmetry in the Aharonov-Casher effect

We consider the problem of the bound states of a spin 1/2 chargless particle in a given Aharonov-Casher configuration. To this end we recast the description of the system in a supersymmetric form. Then the basic physical requirements for unbroken supersymmetry are established. We comment on the possibility of neutron confinement in this system

Ultrasound in the diagnosis of calcium pyrophosphate dihydrate deposition disease. A systematic literature review and a meta-analysis

..

Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report

RATIONALE: Follicular non-Hodgkin lymphoma (fNHL) is a neoplasm characterized by an indolent course and chemosensitivity, but also by disease recurrence. Bendamustine is often used as frontline treatment or second line. HEADING DIAGNOSIS:: fNHL. PATIENT CONCERNS: A 63-year-old Caucasian male with diagnosis of fNHL lymphoma underwent to cyclophosphamide, doxorubicin, vincristine, and prednisone associated with rituximab chemoimmunotherapy, during which interim reevaluation showed progressive disease and severe toxicity. INTERVENTIONS: Early switch to rituximab-bendamustine. OUTCOMES: This regimen was well tolerated, patient compliance was optimal, there were no delays in administration and no infectious episodes. An interim reevaluation after 3 courses revealed that the patient was fit, the blood cell count was normal, and lymphadenopathies and nocturnal sweating had completely regressed. Of note, the PET/CT scan did not show fluorodeoxyglucose pathological uptake, clearly confirming disease regression. LESSONS: Early switching to a bendamustine-rituximab-based scheme, even during conventional chemotherapy, decreases toxicity and reduces the risk of treatment interruption or delay, with favorable effects on overall response and prognosis

Dirac-Foldy term and the electromagnetic polarizability of the neutron

We reconsider the Dirac-Foldy contribution $\mu^2/m$ to the neutron electric polarizability. Using a Dirac equation approach to neutron-nucleus scattering, we review the definitions of Compton continuum ($\bar{\alpha}$), classical static ($\alpha^n_E$), and Schr\"{o}dinger ($\alpha_{Sch}$) polarizabilities and discuss in some detail their relationship. The latter $\alpha_{Sch}$ is the value of the neutron electric polarizability as obtained from an analysis using the Schr\"{o}dinger equation. We find in particular $\alpha_{Sch} = \bar{\alpha} - \mu^2/m$ , where $\mu$ is the magnitude of the magnetic moment of a neutron of mass $m$. However, we argue that the static polarizability $\alpha^n_E$ is correctly defined in the rest frame of the particle, leading to the conclusion that twice the Dirac-Foldy contribution should be added to $\alpha_{Sch}$ to obtain the static polarizability $\alpha^n_E$.Comment: 11 pages, RevTeX, to appear in Physical Review

Irradiation of luminescence dosimeters in pulsed mixed radiation fields

UHDpulse - Metrology for Advanced Radiotherapy using beams with Ultra-High Pulse Dose Rates is a European project aimed at developing novel dosimetry standards, as well as improving existing ones, for FLASH radiotherapy, very high energy electrons radiotherapy, and laser-driven medical accelerators. Within the scope of this project, Thermoluminescence (TL) and Optically Stimulated Luminescence (OSL) detectors are used to measure stray radiation fields. Experiments performed with conventional pulsed particle-beams allow to characterize the dosimeters in known and controllable radiation fields. In turn, this allows to develop models and predict their behavior in complex radiation fields, such as those at laser-driven and FLASH facilities. TL and OSL detectors were irradiated at the Microtron MT25 electron accelerator in Prague, Czech Republic. GAFChromicTM films and plastic nuclear track detectors were used to study the beam profile and the neutron background respectively. The responses of the different detector to the pulsed mixed radiation fields of the Microtron MT25 are compared among each other and presented in this paper

Aharonov-Casher effect for spin one particles in a noncommutative space

In this work the Aharonov-Casher (AC) phase is calculated for spin one particles in a noncommutative space. The AC phase has previously been calculated from the Dirac equation in a noncommutative space using a gauge-like technique [17]. In the spin-one, we use kemmer equation to calculate the phase in a similar manner. It is shown that the holonomy receives non-trivial kinematical corrections. By comparing the new result with the already known spin 1/2 case, one may conjecture a generalized formula for the corrections to holonomy for higher spins.Comment: 9 page

WEIRD Testbeds with Fixed and Mobile WiMAX Technology for User Applications, Telemedicine and Monitoring of Impervious Areas

Wireless Metropolitan Area Networks based on IEEE 802.16d/e standards are soon to be deployed in several countries. However, there is lack of published literature with results from actual test¬beds. This paper introduces the work done in the EU Sixth Framework Programme Project WEIRD to design and set up WiMAX testbeds in four EU countries. We describe the method¬ology followed, detail our implementation and present results from the testbeds, as deployed in the first phase of WEIRD. The testbeds are used to demonstrate how WiMAX technology can be used to extend the connectivity of the pan-European data com¬munications network (GEANT2) to isolated and impervious ar¬eas and, furthermore, to assure end-to-end quality of service to novel applications

WEIRD Testbeds with Fixed and Mobile WiMAX Technology for User Applications, Telemedicine and Monitoring of Impervious Areas

Wireless Metropolitan Area Networks based on IEEE 802.16d/e standards are soon to be deployed in several countries. However, there is lack of published literature with results from actual test¬beds. This paper introduces the work done in the EU Sixth Framework Programme Project WEIRD to design and set up WiMAX testbeds in four EU countries. We describe the method¬ology followed, detail our implementation and present results from the testbeds, as deployed in the first phase of WEIRD. The testbeds are used to demonstrate how WiMAX technology can be used to extend the connectivity of the pan-European data com¬munications network (GEANT2) to isolated and impervious ar¬eas and, furthermore, to assure end-to-end quality of service to novel applications.SIGARCH, Create-NetPublishedInnsbruck, Austria1.4. TTC - Sorveglianza sismologica delle aree vulcaniche attiveope

The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.

Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome. Biomarkers of CLL progression are required for optimising prognosis and therapy. The Inhibitor of Bruton's tyrosine kinase-isoform α (IBTKα) gene encodes a substrate receptor of Cullin 3-dependent E3 ubiquitin ligase, and promotes cell survival in response to the reticulum stress. Searching for novel markers of CLL progression, we analysed the expression of IBTKα in the peripheral blood B-cells of CLL patients, before and after first line therapy causing remission. The expression of IBTKα was significantly increased in disease progression, and decreased in remission after chemotherapy. Consistently with a pro-survival action, RNA interference of IBTKα increased the spontaneous and Fludarabine-induced apoptosis of MEC-1 CLL cells, and impaired the cell cycle of DeFew B-lymphoma cells by promoting the arrest in G0/G1 phase and apoptosis. Consistently, RNA interference of IBTKα up regulated the expression of pro-apoptotic genes, including TNF, CRADD, CASP7, BNIP3 and BIRC3. Our results indicate that IBTKα is a novel marker of CLL progression promoting cell growth and resistance to apoptosis. In this view, IBTKα may represent an attractive cancer drug target for counteracting the therapy-resistance of tumour cells